Amoxicillin,
does it really help with Meaningful shortening of symptoms and disease-specific quality-of-life impairment in clinically diagnosed adult acute rhinosinusitis?
research showsThe grade is C. Garbutt failed its day-3 SNOT-16 primary result, but Cochrane found a statistically significant small cure benefit in clinically diagnosed patients, OR 1.25 (95% CI 1.02 to 1.54), NNTB 19.
ads claimThe ability of an antibiotic to suppress susceptible bacteria is expanded into rapid, marked recovery for most clinically diagnosed cases.
Useful facts when choosing a product
- The pivotal trial used amoxicillin 1,500 mg per day in three divided doses for 10 days and allowed symptomatic medicines for all participants.
- The distinction is 166 randomized versus 155 who actually completed the reported unimputed day-3 follow-up.
- Verdict 1132, which is B with 76 points, concerns Helicobacter pylori eradication with vonoprazan combination therapy; verdict 779, which is F with 8 points, concerns acute bronchitis. Neither indication is this rhinosinusitis claim.
Chamgap Semantic Classification Code
Candidate index · review held
M.amoxicillin.UNK.meaningful-shortening-of-symptoms-and-disease-specific-quality-of-life-impairment-in-clinically-diagnosed-adult-acute-rhinosinusitis.reduce.placeboMedicinal interventions > Amoxicillin > Unknown > Meaningful shortening of symptoms and disease-specific quality-of-life impairment in clinically diagnosed adult acute rhinosinusitis > Reduction claim > Placebo
An automated migration candidate, not an issued permanent code; exact claim scope remains under review. This machine-generated migration candidate helps retrieval but is not a permanent assignment. The original verdict ID and URL remain authoritative.
What the research actually shows
Garbutt randomized 166 and stated an intention-to-treat approach, but 155 participants actually completed the reported unimputed day-3 follow-up. The day-3 SNOT-16 difference was 0.03 (95% CI -0.12 to 0.19), and the day-7 difference was 0.19 (95% CI 0.024 to 0.35). The prespecified clinically important difference of 0.5 points was stated in the Garbutt paper for the same disease and scale. Cochrane reported cure OR 1.25 (95% CI 1.02 to 1.54), NNTB 19, in clinically diagnosed patients. The individual and pooled results differ, but the pooled benefit is statistically significant and small.
Why this is classified as C (50)
The individual day-3 result was null but pooled cure was statistically significant. The average benefit was small, with an NNTB of 19, and day-3 follow-up included 155 of 166 randomized participants, yielding C with 50 points.
Counterpoint. Severe systemic illness, suspected orbital or intracranial complications, immunocompromise, worsening, or prolonged illness falls outside the usual self-limited population and requires clinical assessment.
Rejudgment record. Cross-check applied — Primary-endpoint failure in 166 intention-to-treat participants, a confidence interval excluding the MCID, and small pooled absolute benefit
| Endpoint | P | Symptom or function itself is the target - including patient reports and performance tests |
| Replication | R0 | Trials conflict in direction |
| Independence | I2 | Decisive evidence is publicly or non-profit funded |
| Effect size | E~ | Statistically positive but below the threshold |
Stored derived and displayed grades match; this is not a current recalculation or validity check (C).
Sub-claim grades by effect
This ingredient is marketed for several effects. A single overall grade blends strong and weak claims together, so each effect is graded separately here. The overall grade reflects the strongest disconfirming or core claim.
| Effect (sub-claim) | Grade | Basis |
|---|---|---|
| Meaningful improvement in disease-specific quality of life at day 3 | D | The primary endpoint failed and was far below the 0.5 MCID. |
| Increased clinical cure at 7 to 14 days | C | The pooled effect was small, about 5% absolute benefit with an NNTB of 19. |
| Marked shortening of symptom duration | D | No consistent clinically large shortening was demonstrated. |
Cross-check — AI research and Codex final gate
Evidence Table
| Study | Design | Sample | Funding | Endpoint | Result | Weight |
|---|---|---|---|---|---|---|
| Garbutt JM et al. 2012 | Randomized double-blind placebo-controlled intention-to-treat trial | 166 randomized; 155 completed the reported unimputed day-3 follow-up | Public funding from the US NIAID, grant U01-AI064655-01A1 | Improvement in disease-specific quality of life by day-3 SNOT-16 | -0.59 versus -0.54; between-group difference 0.03 (95% CI -0.12 to 0.19), a failed primary endpoint far below the 0.5 MCID. | Key independent randomized trial |
| Lemiengre MB et al. 2018 Cochrane | Systematic review and meta-analysis of antibiotics versus placebo | 15 trials and 3,057 participants | Academic Cochrane synthesis; included trials had mixed public, academic, and some industry funding | Clinical cure at 7 to 14 days | OR 1.25 (95% CI 1.02 to 1.54) in clinically diagnosed cases, about 5% absolute benefit, NNTB 19. | Overall effect-size synthesis |
Receipt — 2 References
All 2 cited sources were verified for existence at the original page (as of 2026-07-24).
Final verification and publication gate: Codex · Evidence date: 2026-07-24 · Corrections: none
Cite this verdict
[Chamgap] Amoxicillin x meaningful shortening of recovery in adult acute rhinosinusitis — Evidence Grade C·50. 2 cited sources checked. Source: https://chamgap.com/en/verdicts/general/amoxicillin-adult-acute-rhinosinusitis-symptom-recovery/ · CC BY 4.0CC BY 4.0 — free to use with attribution; do not distort grades, numbers, or verdict meaning.
What this document does and does not do
Chamgap is an information source. It reports what research has and has not confirmed; it does not tell readers what to take or buy. That decision belongs to readers and, when needed, medical or legal professionals. This verdict reflects literature available up to the search date and may change as new research appears. Nothing here is medical advice.